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Abstract: The 14-3-3 protein family are molecular chaperones involved in several biological functions
and neurological diseases. We previously pinpointed YWHAZ (encoding 14-3-3ζ) as a candidate gene
for autism spectrum disorder (ASD) through a whole-exome sequencing study, which identified a
frameshift variant within the gene (c.659-660insT, p.L220Ffs*18). Here, we explored the contribution
of the seven human 14-3-3 family members in ASD and other psychiatric disorders by investigating
the: (i) functional impact of the 14-3-3ζ mutation p.L220Ffs*18 by assessing solubility, target binding
and dimerization; (ii) contribution of common risk variants in 14-3-3 genes to ASD and additional
psychiatric disorders; (iii) burden of rare variants in ASD and schizophrenia; and iv) 14-3-3 gene
expression using ASD and schizophrenia transcriptomic data. We found that the mutant 14-3-3ζ
protein had decreased solubility and lost its ability to form heterodimers and bind to its target tyrosine
hydroxylase. Gene-based analyses using publicly available datasets revealed that common variants
in YWHAE contribute to schizophrenia (p = 6.6 × 10−7), whereas ultra-rare variants were found
enriched in ASD across the 14-3-3 genes (p = 0.017) and in schizophrenia for YWHAZ (meta-p = 0.017).
Furthermore, expression of 14-3-3 genes was altered in post-mortem brains of ASD and schizophrenia
patients. Our study supports a role for the 14-3-3 family in ASD and schizophrenia.
Keywords: autism; 14-3-3 gene family; rare variants; common variants; transcriptomics;
schizophrenia; YWHAZ; YWHAE
1. Introduction
Autism spectrum disorder (ASD) is characterized by impairments in communication and social
interactions, and the presence of repetitive and restrictive behaviours [1]. However, the clinical picture
is often accompanied by additional features, such as intellectual disability (ID), epilepsy, language
impairment, anxiety, sleep disorders, and attention-deficit hyperactivity disorder (ADHD) [2]. ASD has
a prevalence of approximately 1.5% in the general population [3,4] and large studies suggest an
unequivocal genetic contribution to its aetiology. Indeed, family and twin studies indicate a heritability
of around 80%, which represents one of the highest amongst neuropsychiatric disorders [5–7]. Despite
the substantial role of genetic factors in the disorder, the genetic architecture is not fully dissected
and many of the underlying genes are yet to be identified. Also, the genetic relationships amongst
comorbid phenotypes remain largely unknown.
Genetic studies suggest a multi-hit model of inheritance in which a combination of risk alleles,
including both common variants of small effect size and rare variants with higher penetrance, contribute
to the phenotype [8,9]. Despite the large number of association studies in the last decade, the robust
identification of common risk alleles for ASD has been elusive, and the first genome-wide association
studies (GWAS) performed with reasonably large samples [10–12] pinpointed associations with
single nucleotide polymorphisms (SNPs) that were subsequently not replicated in a large European
sample [13]. A GWAS recently performed in 18,381 ASD patients and 27,969 controls identified
five genome-wide significant loci [14], suggesting the need of large samples to identify common
risk variants. Regarding rare variants in ASD, the first whole-exome sequencing (WES) studies
focused on de novo variants and suggested a substantial role for this class of damaging mutations
in the aetiology of the disorder [15–17]. These approaches were crucial to pinpoint novel genes
involved in the disorder [18], and recently the largest WES study reported 102 ASD risk genes in a
sample of 11,896 cases [19]. WES studies were also performed to address the impact of rare inherited
variants [18,20–22]. We performed the first WES study in multiplex families with autism that suggested
a role for genome-wide truncating mutations in the aetiology of ASD [22]. A current genetic model
would implicate a higher number of gene-disrupting variants in severe ASD phenotypes, increasing
symptom severity and comorbidity with ID [2,19].
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In our first WES study [22] we identified a truncating mutation in the YWHAZ gene (c.659-660insT,
p.L220Ffs*18) that was transmitted from a mother with depression to an ASD sib-pair. In that previous
study, the YWHAZ gene was the main interconnected node in a network including mutated genes
identified by previous WES studies and other genes implicated in ASD. This gene encodes 14-3-3ζ,
a protein involved in a range of biological processes including cell cycle, transcription, neuronal
development, migration and neurite outgrowth [23–25]. 14-3-3ζ is one of the seven members (β, γ, ε,
η, ζ, σ, θ) of the highly conserved 14-3-3 protein family. These proteins exert their function as homo-
and heterodimers through protein-protein interaction with a wide range of target proteins, typically
binding to phosphorylated serine and threonine residues [26]. Several studies have demonstrated
the role of YWHAZ and other family members in neurogenesis and neurodifferentiation, and its
possible implication in neurodevelopmental disorders [24,27]. Recent studies suggested that decreased
14-3-3ζ protein levels in ASD may be responsible for deficits in melatonin synthesis observed in
ASD via the downregulation of the aralkylamine N-acetyltransferase (AANAT) and acetylserotonin
o-methyltransferase (ASMT) enzymatic activity [28–30]. Moreover, YWHAZ knock-out mice show
impaired cortical development and larger lateral ventricles, reduced dendritic and synaptic density,
aberrant neuronal migration in hippocampus, abnormal mossy fibers connectivity, and cognitive
deficits [31–33].
Interestingly, several members of the 14-3-3 gene family have been implicated in psychiatric
disorders, including reported associations of YWHAB, YWHAE, YWHAZ and YWHAH with
schizophrenia [34–39]; YWHAE and YWHAQ with ADHD [39]; YWHAH, YWHAG and YWHAE with
bipolar disorder [39,40]; YWHAE and YWHAQ with major depressive disorder [39,41]; and YWHAE
with suicide attempts [42]. However, most of these studies were performed in small samples and
lacked replication in larger populations. Furthermore, altered levels of 14-3-3 proteins were found in
the blood or brains of patients with ASD [29,43,44], schizophrenia [45–48] and bipolar disorder [48].
Interestingly, microduplications of YWHAE, which encodes 14-3-3ε that form stable heterodimers
with 14-3-3ζ, were reported in ASD patients; whereas microdeletions involving both YWHAE and
PAFAH1B1 genes cause Miller–Dieker syndrome, a form of lissencephaly with ID and seizures [49–53],
and deletions including YWHAG and HIP1 were related to epilepsy, learning problems and ID [54].
Animal models deficient for 14-3-3 proteins show a variety of behavioural manifestations related
to psychiatric disorders: Ywhaz (14-3-3ζ) deficient mice present hyperactivity, impaired memory,
lower anxiety and impaired sensorimotor gating [32,33]; Ywhae (14-3-3ε) deficient mice present
enhanced anxiety-like behaviour, defects in working memory, increased locomotor activity and
sociability [34,55]; and heterozygous knock-out mice deficient for Ywhag (14-3-3γ) show hyperactivity
and depressive-like behaviour [56]. Furthermore, a recent study reported that the specific inhibition of
14-3-3 proteins in the hippocampus of mice is sufficient to cause hyperactivity, reduce sensorimotor
gating and impair associative learning and memory [57].
Based on these aforementioned reports, we hypothesize that the 14-3-3 gene family may play an
important role in the susceptibility to psychiatric disorders. Thus, here we aim to: (i) gain molecular
insight for the role of the YWHAZ truncating mutation p.L220Ffs*18 previously reported in a family
with distinct psychiatric disorders; (ii) assess the contribution of common and rare variants of the
14-3-3 gene family (SFN, YWHAB, YWHAE, YWHAG, YWHAH, YWHAQ and YWHAZ) to ASD and
other psychiatric disorders; and (iii) explore possible altered expression levels of this gene family in
psychiatric disorders.
2. Experimental Section
2.1. Expression, Purification and Solubility Testing of Recombinant 14-3-3ζ Wild-Type and Mutated Proteins
The recombinant human YWHAZ wild-type (WT) and mutant were expressed in E. coli
using pGEX-2TK expression system, and purification of the soluble fractions as fusion proteins
with glutathione-S-transferase (GST) was performed according to previous protocols [58], see also
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supplementary information for details. The 14-3-3ζ mutated protein replicating the C-terminal amino
acid alteration from the p.L220Ffs*18 insertion mutation, was generated using site-directed mutagenesis
as detailed in the supplementary information.
Due to low solubility of the GST-14-3-3ζ_mut protein we tested expression and solubility at
different temperatures (induction time, h) of 30 (4 h), 25 (5 h) and 20 (6 h) ◦C and compared total
and soluble lysate to that of WT on sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE, see supplementary information for details).
2.2. Functional Assessment of 14-3-3ζ WT and Mutant Proteins by Surface Plasmon Resonance
One of the best-characterized binding targets of 14-3-3 proteins is tyrosine hydroxylase (TH)
phosphorylated at serine 19 (THpSer19) [58,59]. Human TH was purified and phosphorylated on
serine 19 using p38 regulated/activated protein kinase (PRAK, also referred to as MK2) as previously
described [60]. The WT and mutated 14-3-3ζ proteins were assessed for their binding to THpS19 or
non-phosphorylated TH using surface plasmon resonance (Biacore 3000, Cytiva, Marlborough, MA,
USA) as previously described [58,60]. GST-14-3-3 proteins were immobilized on CM5 sensor chips
according to manufacturer’s instructions using the GST-capture kit (Cytiva) giving similar amounts of
immobilized GST-14-3-3ζ_WT and GST-14-3-3ζ_mut. Target protein binding was assessed at 25 ◦C,
using the HBS-P Buffer provided by the manufacturer (10 mM HEPES pH 7.4, 150 mM NaCl and
0.005% polysorbate 20). Different concentrations of Ser19 phosphorylated TH were injected multiple
times for multiple immobilizations. We used the unphosphorylated TH as a negative control of the
binding. The resulting sensograms were analyzed with the BIAevaluation v3.2 software (Biacore AB,
Uppsala, Sweden).
2.3. Assessing the Dimerization of Mutant and Wild-Type Proteins (14-3-3ζ and 14-3-3σ) in Cells by
Bioluminescence Resonance Energy Transfer (BRET) Assay
Plasmids were obtained for expressing fusion proteins of different 14-3-3 members (14-3-3ζ, 14-3-3ε,
14-3-3σ) with Rluc (Renilla luciferase, donor) and EYFP (enhanced yellow variant of GFP, acceptor),
as described in the supplementary information. The ability of mutant 14-3-3ζ to form heterodimers
with 14-3-3ε, and of mutant 14-3-3σ to form homodimers, was assessed using a bioluminescence
resonance energy transfer (BRET) assay.
Human embryonic kidney cells (HEK-293T) were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin
(GIBCO, Carlsbad, CA, USA), in a 5% CO2 humidified atmosphere at 37 ◦C. The cell line was grown in
6-well plates (35-mm-diameter wells) at a density of 5.0 × 105 cells/well for transfection using CaCl2
as described in the supplementary information. Cells were co-transfected with the cDNA construct
coding for Rluc-target-protein-1, acting as BRET donor, and increasing amounts of the cDNA construct
coding for YFP-target-protein-2 as BRET acceptor (see Table S1 for the amounts of cDNA used). D(1A)
dopamine receptor (DRD1) fusion protein with YFP or Rluc [61] was used as a negative control of the
dimerization, and co-transfected with the corresponding tested constructs (Table S1). After 48 h upon
transfection, cells were washed twice with Hanks’ balanced salt solution pH 7.4 (HBSS, 137 mM NaCl,
5 mM KCl, 1.26 mM CaCl2, 0.4 mM MgSO4, 0.5 mM MgCl2, 0.34 mM Na2HPO4, 0.44 mM KH2PO4,
10 mM HEPES) supplemented with 1% glucose (w/v), detached and resuspended in the same buffer.
Protein concentration was determined using the Bradford assay kit (Bio-Rad, Munich, Germany) and
all cell suspensions were diluted with HBSS to obtain a final concentration of 0.2 mg/mL of protein.
In order to quantify fluorescence, cell suspensions (20 µg of protein) were distributed in duplicates
in a 96-well black microplate with a transparent bottom (Porvair, King’s Lynn, UK). Fluorescence was
then measured using a FLUOstar Optima fluorimeter (BMG Labtechnologies, Offenburg, Germany)
equipped with a high-energy xenon flash lamp, and a 10 nm bandwidth excitation filter at 400 nm
reading. A PHERAstar Flagship FSX fluorimeter (BMG Labtechnologies, Offenburg, Germany) was
used for BRET and luminescence measurements. Cell suspensions (20 µg of protein) were distributed
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in duplicates in a 96-well white opaque microplate (Porvair, King’s Lynn, UK) and coelenterazine
H (Molecular Probes Europe, Leiden, The Netherlands) was added at a final concentration of 5 mM.
One minute after adding coelenterazine H, luminescence readings were collected using sequential
integration of signals detected at 440–500 nm and 510–590 nm. Luminescence measurements of the
same samples were performed after 10 min of incubation with coelenterazine H. Cells expressing
BRET donors alone were used to determine background. The BRET ratio is defined as: ((emission at
510–590 nm)/(emission at 440–500 nm))–Cf; where Cf corresponds to (emission at 510–590 nm)/(emission
at 440–500 nm) for the donor construct expressed alone in the same experiment. Data were fitted to
a non-linear regression equation, assuming a single phase saturation curve with GraphPad Prism
software (San Diego, CA, USA).
2.4. Common Variants in the 14-3-3 Family in Autism Spectrum Disorder (ASD): Association Study in
Our Sample
2.4.1. Subjects of Our ASD Cohorts
The cohort used in the case-control association study consisted of 727 ASD patients and 714
gender-matched controls from three European populations: Spanish, Dutch and German (Table S2).
The cohort used for mutational screening employed a subset of 288 ASD patients from the same three
populations (Table S2). All individuals had European ancestry. ASD patients were assessed using
the ADI-R (Autism-Diagnostic Interview-Revised) [62] and, where possible, also the ADOS (Autism
Diagnostic Observation Schedule) [63]. Cytogenetic abnormalities or a positive Fragile X test were
considered exclusion criteria. The study was approved by the relevant ethics committee from each
center and written informed consent was obtained from all parents/guardians or, where possible,
by affected individuals, according to the Helsinki Declaration. Genomic DNA was extracted from
peripheral blood samples using the standard salting-out method [64].
2.4.2. Common Variant Association Study of the 14-3-3 Family in Our ASD Sample
SNP selection was performed to encompass common genetic variants across the seven genes of the
14-3-3 family (SFN, YWHAQ, YWHAG, YWHAZ, YWHAB, YWHAH and YWHAE). Each gene included a
5kb flanking region (both 5′ and 3′), and patterns of linkage disequilibrium (LD) were considered using
the Central European (CEU) panel of HapMap project data (www.hapmap.org; phases 1, 2, 3; release 28).
A total of 42 tagSNPs were selected using the Tagger implementation in HaploView v4.2 [65], according
to the following criteria: r2 ≤ 0.8 and minor allele frequency (MAF) ≥ 0.05. The sample of 1441 subjects
was genotyped using iPlex-Sequenom technology (Sequenom, San Diego, CA, USA) at the Spanish
National Genotyping Center (CeGen). Duplicates were included as controls for genotyping quality.
After quality control procedures, 36 individuals with genotyping rate lower than 90% were removed
from the study, setting the final sample to 1405 individuals (713 cases and 692 controls). From the
42 SNPs initially genotyped, four assays failed, and one SNP was monomorphic. The genotyping
rate for the 37 remaining SNPs was 99.2%. One of the SNPs was excluded for quality reasons, but all
the remaining 36 SNPs were in Hardy–Weinberg equilibrium (threshold set at p < 0.01 in controls).
Thirty-four SNPs showed a MAF > 0.05 in our sample and were examined for association with ASD
(Table S3). LD patterns and D’ values were determined in our sample data with Haploview v4.2 [65]
(Figure S1). A case-control association study under the additive model was run with the PLINK
package [66].
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2.5. Common Variant Associations with the 14-3-3 Gene Family across Psychiatric Disorders Using Public
Genome-Wide Association Studies (GWAS) Data
We assessed the contribution of common variation in the seven 14-3-3 genes to psychiatric disorders
using GWAS summary statistics from the Psychiatric Genomics Consortium (PGC), Broad Antisocial
Behaviour Consortium (BroadABC) and Integrative Psychiatric Research Consortium (iPSYCH).
We considered the following phenotypes: attention-deficit/hyperactivity disorder (ADHD) [67],
anti-social behaviour (ASB) [68], anxiety [69], autism spectrum disorder (ASD) [14], bipolar disorder
(BD) [70], major depressive disorder (MDD) [71], obsessive-compulsive disorder (OCD) [72],
schizophrenia [73] and cross-disorder meta-analysis [74] (see details in Table S4). All summary
statistics used for subsequent analysis had a MAF ≥ 0.01 and info-score for imputation quality ≥ 0.6.
A gene-based association study was performed with MAGMA (v1.06) [75] using the 1000 Genomes
Project Phase 3 (Build 37/European data only) as a reference panel. We also performed a self-contained
gene-set analysis considering the whole 14-3-3 gene family for each of the eight psychiatric phenotypes
and for the cross-disorder meta-analysis.
2.6. Rare Variant Analysis of the 14-3-3 Gene Family: Mutational Screening in Our ASD Sample
The seven genes of the 14-3-3 family were analyzed in 288 Caucasian ASD patients by
high-throughput sequencing using the Ion Torrent platform (ThermoFisher Scientific, Waltham,
MA, USA) at the Centre for Research in Agricultural Genomics (CRAG). A total of 57 tagged-primer
pairs were designed with the Ion Ampliseq Designer (ThermoFisher Scientific) and covered 96.3% of all
coding exons across the 14-3-3 gene family (Table S5), including the splice sites and part of the 5′ and
3′ untranslated regions (UTR) (Figure S2). The corresponding amplicons were sequenced in 288 ASD
patients (182 Spanish, 94 Dutch, 12 Germans), including the MT_160.3 patient, heterozygous carrier for
the previously described c.659_660insT mutation leading to p.L220Ffs*18 in the YWHAZ gene [22], as a
positive control. Genomic DNA was pooled in groups of three subjects to minimize costs. The results
were processed using the Ion Reporter Software (ThermoFisher Scientific) under somatic variant calling
parameters to identify low-frequency variant calls (average read depth 1400X), and the function Variant
Analysis of the Ingenuity Pathway Analysis software (http://www.ingenuity.com/products/ipa) was
employed to assess the identification and the molecular nature of the variants identified in our sample.
To handle analysis of pooled sequencing, every single change identified in a pool was subjected to
Sanger validation in the three subjects present in the reaction, in order to confirm the variant and
determine the carrier status of each individual.
2.7. Rare Variant Analysis of the 14-3-3 Gene Family: ASD and Schizophrenia Public Datasets
The impact of rare variants across the seven genes of the 14-3-3 family was assessed
and further extended using publicly available sequencing data of schizophrenia, ASD and
control cohorts from the following sources: (i) whole-exome sequencing (WES) from the Sweden-
Schizophrenia population-based case-control (database of Genotypes and Phenotypes (dbGAP)
accession: phs000473.v2.p2) (6135 cases and 6245 controls); (ii) ARRA Autism Sequencing Collaboration
(dbGAP accession: phs000298.v3.p2) (1288 unrelated ASD probands); (iii) European ASD samples,
which included our previously sequenced sample of 288 ASD patients plus 348 additional ASD
patients from Germany; (iv) Medical Genome Reference Bank (2845 healthy Caucasian Australians
aged > 75). The selection of variants was based on: (1) their predicted pathogenicity using the
Variant Effect Predictor annotation tool software (https://www.ensembl.org/Tools/VEP): missense
mutations predicted to be damaging in both SIFT (Sorting Intolerant From Tolerant) and Polyphen2
(Polymorphism Phenotyping v2)), and with CADD (Combined Annotation Dependent Depletion) > 20
for canonical splice site variants, stop codon mutations and indels leading to frameshift; and (2) minor
allele frequency (MAF < 0.0001) in non-Finnish European populations from the Genome Aggregation
Database (http://gnomad.broadinstitute.org/) as previously described [18]. A chi-square statistic was
used to compare the schizophrenia patient sample (6135 cases) and combined ASD datasets (1924 cases)
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with the combined control datasets (9090 individuals). Additionally, we explored the impact of
rare variants for each of the 14-3-3 genes as reported by the Autism Sequencing Consortium (ASC)
(https://asc.broadinstitute.org/) and the Schizophrenia Exome-sequencing Meta-Analysis (SCHEMA)
(https://schema.broadinstitute.org/). ASC represents the largest source of data of rare variants for
genetic studies of ASD, which includes de novo variant calls for 6430 probands and 2179 unaffected
siblings (family-based dataset), and rare variants identified in 5556 ASD patients and 8809 controls
(case-control dataset). Similarly, SCHEMA combines data for rare variants across several world-wide
populations with a joint sample of 24,248 schizophrenia patients and 97,322 controls (case-control
dataset), and 3444 schizophrenia trios (family-based dataset).
2.8. Expression of the 14-3-3 Genes in Autism Spectrum Disorder and Schizophrenia
Differential expression of the seven 14-3-3 genes was assessed using transcriptomic data from
post-mortem brain regions of ASD and schizophrenia patients in publicly available human datasets,
either in the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) or in published
articles. We found 39 studies with available information on gene expression in brain: 12 in ASD
patients and 27 in schizophrenia patients. In particular, in the case of ASD we analysed data on
altered gene expression in brain from 11 papers and one GEO dataset (PubMed ID: 27919067, 29859039,
21614001, 22457638, 22984548, 18006270, 18378158, 25494366, 27219343, 27685936, 30545856 and
GSE38322). For schizophrenia we analysed data on brain gene expression from 14 papers (30545856,
25113377, 24287731, 21091092, 24167345, 23904455, 24686180, 24886351, 22031440, 18778695, 26818902,
22212594, 22954356, 29931221) and 13 GEO datasets (GSE46509, GSE37981, GSE21935, GSE21138,
GSE17612, GSE12654, GSE87610, GSE53987, GSE62191, GSE35977, GSE12649, GSE12679, GSE35978).
Differential expression was assessed in multiple brain areas, including hippocampus, cerebellum or
cortex, depending on the dataset.
3. Results
3.1. Functional Effect of the YWHAZ (14-3-3ζ) Mutation p.L220Ffs*18
We firstly aimed to assess the functional consequences of a truncating variant (c.659_660insT,
p.L220Ffs*18) previously identified in the YWHAZ gene and transmitted from a mother with depression,
phobia and fibromyalgia to two siblings both with ASD and attention-deficit hyperactivity disorder
(ADHD) [22]. The maternal grandmother was diagnosed with schizophrenia (Figure 1A), although
DNA from this case was unfortunately not available for mutation analysis.
This truncating variant does not meet criteria to trigger degradation of the corresponding mRNA
by nonsense-mediated RNA decay (NMD), since it is located 22 nucleotides before the last exon-exon
junction (Figure 1B) [76,77]. Therefore, we performed experiments to investigate the possible functional
effect of p.L220Ffs*18 on the protein by assessing: (i) its solubility; (ii) its ability to bind tyrosine
hydroxylase (TH), one of its natural targets when phosphorylated at its 14-3-3 binding site (THpSer19);
and (iii) its capacity to form heterodimers with 14-3-3ε.
The mutated 14-3-3ζ protein (p.L220Ffs*18) showed decreased solubility compared to the WT
14-3-3ζ when it was expressed in prokaryotes (E. coli) (Figure 1C,D). The solubility did not show any
improvement at different temperatures for the mutated protein (Figure 1C). The fraction of soluble
mutated protein was lower than 5% (compared to 90% for the WT protein), with the vast majority
remaining insoluble in the lysate fraction (Figure 1D).
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Figure 1. Mutation identified in YWHAZ in two siblings with ASD. (A) Pedigree of the family carrying 
the c.659-660insT mutation in YWHAZ and below the Sanger sequence of the truncating variant. 
Abbreviations: ADHD, attention-deficit hyperactivity disorder; ASD, autism spectrum disorder; CD, 
conduct disorder; IQ, intelligence quotient; OCD, obsessive-compulsive disorder; SCZ, 
schizophrenia. [=], wild-type allele; [?], unknown genotype. (B) Location of the mutation in the 
YWHAZ gene, and comparison of the last amino acids of the wild-type (WT) and mutant (Mut) 14-3-
3ζ protein, showing in red the amino acids that diverge in the mutant protein. (C) Coomassie stained 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of glutathione-S-
transferase (GST)-14-3-3ζ (WT and mutant) expressed in E. coli strain at different temperatures. 
Aliquots of the bacteria were lysed, and the amount of soluble protein was assessed by comparing 
total lysate (Lys) to supernatant after centrifugation of the lysate (Sup) for wild-type 14-3-3ζ (WT) and 
mutant 14-3-3ζ (Mut). (D) Quantification of solubility by measuring the major GST-14-3-3 band (55 
kDa) for WT and Mut expressed at 30 °C. Data presented as means and error bars denote the standard 
deviation (n = 3; p = 1.7× 10−3 for Mut Lys vs. Mut Sup; p = 1.4 × 10−4 for WT Sup vs. Mut Sup; t-test, 
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Figure 1. Mutation identified in YWHAZ in two siblings with ASD. (A) Pedigree of the family
carrying the c.659-660insT mutation in YWHAZ and below the Sanger sequence of the truncating
variant. Abbreviations: ADHD, attention-deficit hyperactivity disorder; ASD, autism spectrum
disorder; CD, conduct disorder; IQ, intelligence quotient; OCD, obsessive-compulsive disorder; SCZ,
schizophrenia. [=], wild-type allele; [?], unknown genotype. (B) Location of the mutation in the
YWHAZ gene, and comparison of the last amino acids of the wild-type (WT) and mutant (Mut) 14-3-3ζ
protein, showing in red the amino acids that diverge in the mutant protein. (C) Coomassie stained
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of glutathione-S-transferase
(GST)-14-3-3ζ (WT and mutant) expressed in E. coli strain at different temperatures. Aliquots of the
bacteria were lysed, and the amount of soluble protein was assessed by comparing total lysate (Lys)
to supernatant after centrifugation of the lysate (Sup) for wild-type 14-3-3ζ (WT) and mutant 14-3-3ζ
(Mut). (D) Quantification of solubility by measuring the major GST-14-3-3 band (55 kDa) for WT and
Mut expressed at 30 ◦C. Data presented as means and error bars denote the standard deviation (n = 3;
p = 1.7 × 10−3 for Mut Lys vs. Mut Sup; p = 1.4 × 10−4 for WT Sup vs. Mut Sup; t-test, two sided).
The 14-3-3 proteins exert their function as homo- or heterodimers through binding to their target
proteins, usually in a Ser/Thr phosphorylation-dependent manner [78]. We assessed the ability of
14-3-3ζ p.L220Ffs*18 to bind tyrosine hydroxylase (TH), the rate limiting enzyme in the synthesis
of dopamine and one of its canonical target proteins. WT 14-3-3ζ has previously been reported to
bind with nM affinity to Ser19-phosphorylated TH (THpSer19) (THpSer19) [58,79]. By using surface
plasmon resonance, we found that the mutant protein expressed in prokaryotes (E. coli) lost its ability
to bind the THpSer19 compared to the WT protein (Figure 2A,B).
We further assessed the capacity of both 14-3-3ζ_WT and 14-3-3ζ_mut proteins to interact with
14-3-3ε and form heterodimers, all expressed in a human cell line (HEK 293T cells). Through BRET
assays we were able to detect the interaction between WT 14-3-3ζ and 14-3-3ε, as shown by a positive
and saturable BRET signal (Figure 2C). Our results showed that the mutant 14-3-3ζ lost its capacity to
form heterodimers with 14-3-3ε, since the linear relationship with the acceptor/donor ratio (YFP/Rluc)
suggested lack of interaction (Figure 2C). We used DRD1, not known to be a 14-3-3 target, fused either
to luciferase or to yellow fluorescent protein (DRD1-Rluc and DRD1-YFP) as negative controls.
No interactions were identified, obtaining linear non-specific BRET signals, confirming the specificity
of the WT 14-3-3ζ and 14-3-3ε interaction (Figure S3). Remarkably, when expressed in HEK293T cells
for BRET assays, the 14-3-3ζmutant protein only showed a detectable signal when transfecting at least
10 times the amount of plasmid required for the WT (Table S1), indicating likely protein degradation,
in line with the decreased solubility observed in E. coli.
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tyrosine hydroxylase (25 nM) to immobilized wild-type GST-14-3-3ζ (green) or mutant
GST-14-3-3ζ (blue) using surface plasm resonance (Biacore 3000, see Materials and Methods for
details). The proteins were expressed in the BL21 Codon Plus E. coli strain an urified prior to the
analysis. (B) The binding response for Ser19 phosphorylated tyrosine hydroxylase (25 nM) at the
end of the injection was compared between 14-3-3ζ WT or Mut and Ser19 phosphorylated tyrosine
hydroxylase (TH-pS19) (25 nM) repeated by several immobilizations and injections. Data presented as
means and error bars denote the standard deviation (n = 3, p = 1.61 × 10−8 WT vs. Mut, two-sided
t-test). (C) Characterization of wild-type 14-3-3ζ (YWHAZ WT) and mutant 14-3-3ζ (YWHAZ mut)
interaction with 14-3-3ε (YWHAE) using a bioluminescence resonance energy transfer (BRET) assay.
Rluc-YWHAZ WT co-transfection with an increasing amount of YWHAE-YFP gives a saturable positive
signal (green), whereas the signal obtained co-transfecting Rluc-YWHAZ mut with an increasing
amount of YWHAE-YFP fits with a linear regression (blue). mBU, BRET ratio expressed in milli-BRET
units. The relative amount of BRET is given as a function of YFP/Rluc*100, where YFP corresponds
to the fluorescence signal due to the increasing amount of donor and Rluc corresponds to the stable
luminescence signal measured at 10 min. Values shown correspond to independent experiments (n = 4).
Thus, a damaging effect of the truncating mutation p.L220Ffs*18 on 14-3-3ζ was confirmed,
with loss of function of the altered protein.
3.2. Common Variants Across the 14-3-3 Gene Family in ASD and Other Psychiatric Disorders
We sought for common genetic risk variants in the gene family encoding the 14-3-3 proteins in
ASD and in other psychiatric disorders.
A case-control study was first performed in our sample of 713 ASD patients and 692 controls,
both with European ancestry, investigating the common genetic variability of the 14-3-3 gene family
(SFN, YWHAB, YWHAE, YWHAG, YWHAH, YWHAQ and YWHAZ) tagged by 34 SNPs. Only the
variant rs1883660, located at the 3′UTR of the SFN gene, showed a nominal association with ASD
(p = 0.01), but it did not remain significant after Bonferroni correction for multiple testing (Table S3).
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We further extended the analysis for contribution of common variants in the seven genes of the
14-3-3 family to large GWAS datasets of eight psychiatric disorders, using summary statistics from the
PGC, BroadABC and iPSYCH GWAS datasets (Table S4). The gene-based association study showed
nominal associations for four out of seven genes with several psychiatric disorders: YWHAB with
ADHD and schizophrenia, YWHAE with bipolar disorder and schizophrenia, YWHAZ with MDD and
schizophrenia, and SFN with anxiety (Table 1).
Table 1. Gene-based association analysis of each of the seven 14-3-3 genes across several
psychiatric disorders.
Gene
Symbol
Entrez
ID ADHD ASB Anxiety ASD BD MDD OCD SCZ Cross-Disorder
YWHAB 7529 0.024 0.923 0.098 0.711 0.629 0.777 0.170 0.001 0.050
YWHAE 7531 0.086 0.933 0.190 0.468 0.006 0.154 0.262 1.35 × 10−6 1.01 × 10−5
YWHAG 7532 0.081 0.054 0.111 0.929 0.065 0.854 0.454 0.119 0.169
YWHAH 7533 0.153 0.520 0.218 0.741 0.104 0.658 0.243 0.291 0.410
YWHAQ 10971 0.801 0.438 0.927 0.835 0.637 0.441 0.054 0.300 0.900
YWHAZ 7534 0.262 0.415 0.311 0.125 0.168 0.029 0.771 0.001 0.095
SFN 2810 0.834 0.767 0.045 0.272 0.648 0.849 0.375 0.979 0.966
p-values were calculated using MAGMA (v1.06) software. Nominal associations are highlighted in bold. Underlined
values survived Bonferroni correction for multiple testing, p = 7.9 × 10−4 (7 genes and 9 phenotypes). ADHD:
attention-deficit hyperactivity disorder; ASB: antisocial behaviour; ASD: autism spectrum disorder; BD: bipolar
disorder; MDD: major depression disorder; OCD: obsessive-compulsive disorder; SCZ: schizophrenia.
However, the association found between YWHAE and schizophrenia (p = 1.35 × 10−6; 33,640 cases
and 43,456 controls) was the only surviving Bonferroni correction for 7 genes and 9 phenotypes.
The gene-based results from the cross-disorder meta-analysis combining data across eight psychiatric
disorders also showed a significant association with YWHAE (p = 1.01 × 10−5). We also performed a
combined gene-set association analysis that indicates a nominal association of the whole 14-3-3 gene
family with schizophrenia (p = 0.018) (Table S6).
3.3. Rare Variants in the 14-3-3 Gene Family in ASD and Schizophrenia
We investigated the role of rare variants in the 14-3-3 gene family in ASD and schizophrenia.
First, we used next-generation sequencing to search for rare variants in the seven 14-3-3 genes in 288
ASD patients from our European collection, identifying nine rare variants (Table S7). All variants
were validated by Sanger sequencing and the parental origin was assessed when possible (Table S7).
Two detected variants were predicted to be deleterious and were found in the SFN gene in the same
patient (p.E75del and p.T165S) together with a third variant predicted as benign (p.S149L). All three
variants were present on the same chromosome and transmitted from the mother to an affected ASD
proband (Figure S4A,B). We subsequently assessed the functional effect of 14-3-3σ carrying these three
changes using BRET assays, observing that the mutant protein was still able to interact with both
the WT and the mutated 14-3-3σ protein, as shown by positive saturable signals with similar BRET50
and BRETmax (Figure S4C). The specificity of this interaction was confirmed by negative controls,
obtaining linear non-specific BRET signals (Figure S4D). These results suggest that these rare variants
do not impact dimerization.
We also explored the impact of ultra-rare variants (URV) across the 14-3-3 gene family in an
extended sample of ASD patients, as well as in a sample of schizophrenia patients. For this objective
we used publicly available sequencing data, which comprised 1924 ASD probands, 6135 schizophrenia
patients, and 9090 control individuals. The high degree of evolutionary conservation of the seven
14-3-3 genes [80,81] and the limited sample size, resulted in relatively limited numbers of genetic
variants. This prompted us to combine the data for the whole gene family. Interestingly, a significant
burden of URVs was observed for ASD in the 14-3-3 family when compared to controls (7 in 1924
ASD cases vs. 11 in 9090 controls, p = 0.017), driven by a splice site variant in YWHAE (rs756213490),
which was found in four unrelated ASD probands and not in controls (Table 2).
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Table 2. List of ultra-rare variants (URVs) across the 14-3-3 gene family found in large public datasets.
Chr:position Ref/Alt Gene Data_Set(Controls/Cases)
gnomAD
NFE AF Impact
Amino
Acids SIFT PolyPhen-2 CADD
Existing
Variation
17:1264594 T/A YWHAE ARRA(0/4) 2.19 × 10−5 splice_acceptor_variant
canonical
splice site - - 34 rs756213490
8:101961051 C/A YWHAZ German_ASD(0/1) missense_variant A/S
deleterious
low_confidence
(0.03)
possibly_damaging
(0.799) 26.9 rs774415799
1:27189925 GGA/- SFN Spanish_ASD(0/1) 2.65 × 10−5 inframe_deletion SE/S - - 21.5 rs773116730
8:101936203 A/AT YWHAZ Spanish_ASD(0/1) frameshift_variant frameshift - - - -
2:9731521 G/A YWHAQ Swedish_SCZ(0/1) 8.81 × 10−6 stop_gained Q/* - - 42 rs769768341
8:101936511 G/C YWHAZ Swedish_SCZ(0/1) 8.84 × 10−6 stop_gained S/* - - 40 rs754522887
22:32352395 CAAGGTGTTTTACCTGA/C YWHAH
Swedish_SCZ
(0/1) 8.80 × 10−6 frameshift_variant KVFYLK/X - - 35 rs759467778
1:27189840 T/C SFN MRGB(1/0) 2.64 × 10−5 missense_variant V/A
deleterious
low_confidence
(0.01)
probably_damaging
(0.954) 28.6 rs77608477
1:27190047 A/C SFN MRGB(1/0) missense_variant E/A
deleterious
low_confidence (0)
probably_damaging
(0.929) 26.5 -
1:27190145 C/T SFN MRGB(1/0) missense_variant R/W
deleterious
low_confidence
(0.03)
possibly_damaging
(0.776) 33 -
2:9725474 G/GTGTTAGGTTGT YWHAQ
MRGB
(1/0) frameshift_variant frameshift - - - -
8:101961101 A/C YWHAZ MRGB(1/0) missense_variant L/R
deleterious
low_confidence
(0.01)
probably_damaging
(0.909) 27.4 -
22:32352337 T/C YWHAH MRGB(1/0) 8.79 × 10−6 missense_variant V/A
deleterious
low_confidence (0)
probably_damaging
(0.999) 27.9 rs1196036662
22:32352724 A/G YWHAH MRGB(2/0) missense_variant N/S
deleterious
low_confidence (0)
probably_damaging
(0.991) 26.5 -
1:27189780 T/G SFN MRGB(1/0) 8.80 × 10−6 missense_variant M/R
deleterious
low_confidence
(0.01)
possibly_damaging
(0.631) 27.7 rs747687239
1:27190388 CTG/C SFN Swedish_control(1/0) 8.81 × 10−6 frameshift_variant frameshift - - 35 rs774524068
17:1264594 T/A YWHAE Swedish_control(1/0) 2.19 × 10−5 splice_acceptor_variant
canonical
splice site - - 34 rs756213490
ARRA_c1, ASD cases from ARRA c1 data set (dbGAP accession: phs000298.v3.p2); German_ASD, ASD samples from Germany; MGRB, Medical Genome Reference Bank; Spanish_ASD,
ASD samples from Spain; Swedish_SCZ, Sweden-Schizophrenia population-based Case-Control (dbGAP accession: phs000473.v2.p2);. All the URVs variants are selected to be rare
(MAF < 0.0001 in Non-Finish European population in gnomAD, https://gnomad.broadinstitute.org/) and predicted to be pathogenic both in SIFT and, and CADD > 20.
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No significant burden was identified for schizophrenia (3 in 6135 cases vs. 11 in 9090 controls,
p = 0.71). It is noteworthy that truncating variants in YWHAZ are reported here only in patients
(i.e., the frameshift c.659_660insT found in the ASD family functionally investigated here, and a stop
mutation rs754522887 found in a Swedish schizophrenia patient), and they were not observed in the
control group. Furthermore, we also explored large available datasets of ASD and schizophrenia
from the Broad Institute for enrichment of rare variants, and observed that when the 14-3-3 genes
were considered individually, only YWHAZ reached significance for a higher number of SNVs in
schizophrenia (meta-analysis p = 0.017).
3.4. Altered Expression of the 14-3-3 Genes in ASD and Schizophrenia
Finally, we explored potential alterations of expression of the 14-3-3 genes in post-mortem brains
of ASD and schizophrenia patients using transcriptomic datasets or literature reports. From the
39 studies with available information on gene expression in the brain (12 in ASD patients and 27 in
schizophrenia patients), we found 11 studies reporting significant altered expression in 14-3-3 genes
(p < 0.05) in ASD or schizophrenia. Seven of them reported altered 14-3-3 genes expression with a false
discovery rate (FDR) < 0.1.
We found altered expression of six of the seven 14-3-3 genes in at least one of the two phenotypes
compared to control subjects (p < 0.05, FDR < 0.1) (Table 3). All six genes, except for SFN, showed
a decreased expression in different brain areas. Interestingly, five of these genes showed alterations
in expression in both ASD and schizophrenia: YWHAB, YWHAE, YWHAH and YWHAZ showed
decreased expression whether SFN showed increased expression in both disorders. In the case of
YWHAQ, we found decreased expression only in ASD patients compared to controls (Table 3).
Table 3. Altered expression of the 14-3-3 genes in individuals with schizophrenia or autism
spectrum disorder.
Gene
Symbol Disorder FC
& p-Value FDR Probe Tissue Study (PMID)or GEO ID
Sample, Cases
vs. Controls
YWHAB SCZ −1.06 2.51 × 10−3 0.10 8062880 cerebellum GSE35978 44 SCZ vs. 50control
YWHAB SCZ −1.41 0.001 0.02 217717_s_at * hippocampus GSE53987 15 SCZ vs. 18control
YWHAB ASD N/A N/A 1.43 × 10−3 N/A cortex (BA19,BA10, BA44)
Gupta et al.,
2014 (25494366)
32 ASD vs. 40
control
YWHAE ASD −1.34 0.003 0.06 ILMN_1807535 cerebellum GSE38322 15 ASD vs. 12control
YWHAE SCZ −1.52 1.93 × 10−4 0.01 210317_s_at hippocampus GSE53987 15 SCZ vs. 18control
YWHAE SCZ −1.10 3.31 × 10−4 0.04 11753092_s_at * DLPFC GSE87610 65 SCZ vs. 72control
YWHAH SCZ −1.68 6.69 × 10−5 0.01 201020_at hippocampus GSE53987 15 SCZ vs. 18control
YWHAH ASD N/A <0.01 <0.078 N/A DLPFC Liu et al., 2016(27685936)
34 ASD vs. 40
control
YWHAQ SCZ −1.02 0.004 0.03 N/A frontal andtemporal cortex
Gandal et al.,
2018 (30545856)
560 SCZ vs. 936
control
YWHAQ SCZ −1.34 2.34 × 10−5 0.01 200693_at * hippocampus GSE53987 15 SCZ vs. 18control
YWHAZ ASD −1.61 3.01 × 10−5 0.01 ILMN_1669286 cerebellum GSE38322 14 ASD vs. 12control
YWHAZ SCZ −1.87 3.07 × 10−5 0.01 200641_s_at * hippocampus GSE53987 15 SCZ vs. 18control
SFN ASD 2.18 0.001 0.03 N/A frontal andtemporal cortex
Gandal et al.,
2018 (30545856)
51 ASD vs. 936
control
SFN SCZ 1.34 7.69 × 10−5 1.33 × 10−3 N/A frontal andtemporal cortex
Gandal et al.,
2018 (30545856)
559 SCZ vs. 936
control
SFN SCZ 1.53 0.010 0.08 33323_r_at * hippocampus GSE53987 15 SCZ vs. 18control
ASD, autism spectrum disorder; SCZ, schizophrenia; FDR, false discovery rate; & FC, fold change was calculated
when log2FC was provided in the study; N/A, data not available; * Genes showing significant differential expression
in independent probe sets targeting different transcripts/exons of the same gene, data shown corresponding to the
probe with the highest fold-change.
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4. Discussion
The 14-3-3 gene family encodes seven proteins that act as effectors of signaling-regulated proteins.
They are highly expressed in the brain during development [82], and are involved in several neuronal
processes, such as differentiation, migration, synaptogenesis, and axon guidance [24,27,31], as well as
metabolic regulation [83]. Their important role in neuronal functions makes them plausible candidate
genes for ASD and other psychiatric disorders. In a previous WES study we identified a truncating
mutation in YWHAZ (encoding 14-3-3ζ), one of the members of the 14-3-3 family, present in two brothers
with ASD [22]. Both individuals were diagnosed also with ADHD. One proband had mild intellectual
disability (IQ of 68) and presented severe conduct disorder, aggressive behaviour and anxiety. The other
proband had a normal IQ (105) and presented fibromyalgia and sleep disorder. Furthermore, in this
family the mother of the ASD sib-pair, carrier of the YWHAZ mutation, presented with depression and
other conditions, including phobia, fibromyalgia, hypothyroidism, asthma and obesity. The maternal
grandmother of the ASD sib-pair was diagnosed with schizophrenia, and a maternal uncle of the two
sibs had ADHD. Unfortunately, the potential segregation of this truncating variant in YWHAZ in the
broader family could not be tested, as DNA collection was not possible. Interestingly, genes involved
in dopamine neurotransmission have been reported to be associated with ADHD and ASD [84–86],
and fibromyalgia and chronic pain have been related to decreased dopaminergic activity [87,88].
The 14-3-3 proteins act as regulators of dopamine synthesis by binding and stabilizing tyrosine
hydroxylase [89]. Our study showed that the mutated protein 14-3-3ζ (p.L220Ffs*18) was not able to
bind the phosphorylated tyrosine hydroxylase, a well-established molecular partner, leading likely to
altered dopamine synthesis. Moreover, the mutated protein presented a decreased solubility when
expressed in E. coli and it was not able to form heterodimers with 14-3-3ε when expressed in a human
cell line. Our results are interesting also from the perspective of understanding the structural basis of
14-3-3 protein functions, as they suggest that the far C-terminal region may be involved in dimerization
and phospho-target interaction, although further experiments would be needed to confirm it.
Previous research indicates that 14-3-3ζ deficient mice (Ywhaz knock-out) display cognitive and
behavioural deficits possibly related to the dopamine system, altered hippocampal development,
defective migration of pyramidal and granular neurons [33,90]. Also, the Ywhaz and Ywhae double
knock-out mice show impaired neurogenesis, neuronal proliferation, differentiation and migration,
and present severe seizures, indicating that both 14-3-3ζ and 14-3-3ε play a critical role during
cortical development [31]. Indeed, 14-3-3 inhibition in certain brain regions in mice leads to impaired
learning, working memory and long-term synaptic plasticity, symptoms that are associated with
schizophrenia-like behaviours [91]. Altogether, these findings support an essential role for the YWHAZ
gene in brain function and development, and together with our current report, highlight its contribution
to neurodevelopmental disorders.
Given the functional evidence of this truncating mutation in YWHAZ, and several studies
that consistently relate the 14-3-3 gene family to behavioural deficits in animal models, we further
investigated the possible contribution of common and rare variants in this gene family to psychiatric
disorders. The association study in our ASD sample failed to identify SNPs associated with the disorder,
although the sample size was limited considering the small effect sizes typical of common variants in
psychiatric disorders [13]. However, a previous study with similar sample size of adult ADHD patients
identified a significant epistatic effect between YWHAE and two other members of this gene family,
YWHAZ and YWHAQ [39]. When extending our analyses into larger samples of the PGC, BroadABC
and iPSYCH, we found that common variants were gene-based associated with several psychiatric
phenotypes in four of the seven 14-3-3 genes (SFN, YWHAB, YWHAE and YWHAZ), although only
the association between YWHAE and schizophrenia survived correction for multiple testing. In line
with this result, several previous studies found an association of genetic variants in YWHAE with
schizophrenia [34,55].
The possible implication of 14-3-3 members in schizophrenia was also suggested in animal studies,
which showed that 14-3-3ε deficient mice present alterations in hippocampal and cortical structures
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due to defects in neurogenesis and neuronal migration [92,93]. In addition, 14-3-3ε deficient mice
exhibit behavioural phenotypes, such as increased motor activity and decreased working memory and
are used as schizophrenia-related models [34,55]. Furthermore, 14-3-3-mediated signaling seems to be
strongly affected in schizophrenia patients [47,48], supporting the association of this protein family with
the disorder. Interestingly, a polymorphism (rs28365859) in YWHAE associated with schizophrenia [34]
correlates with differences in volumes of different brain regions in patients [94,95]. Taken together,
these data support the contribution of YWHAE to schizophrenia and general brain development.
We also investigated the impact of rare variants in a small European sample of ASD sequencing
all seven 14-3-3 genes. We identified 9 rare variants in 3 genes (YWHAE, YWHAB and SFN), including
two rare variants in SFN that were predicted to be pathogenic (p.E75del and p.T165S) and were
present on the same chromosome of the same patient. However, the functional characterization of
the effect of these latter variants showed no effect on dimerization, although they may have other
functional consequences.
We then expanded the analysis of rare variants to larger samples using available sequencing
datasets of ASD and schizophrenia, which pinpointed a plausible impact for rare variants in ASD
when we combined data of all 14-3-3 genes. Interestingly, the effect of this association was driven by
URVs from YWHAE and YWHAZ. Indeed, several exome sequencing studies in ASD patients found
rare variants in YWHAZ and YWHAG [19,96,97]. We also explored sequencing data from the ASC and
SCHEMA consortia for each of the 14-3-3 genes individually and an enrichment was observed only for
SNVs in YWHAZ in the schizophrenia dataset.
Interestingly, both the expression and the splicing of several 14-3-3 genes are regulated by
RNA-binding proteins that are relevant to ASD and other psychiatric disorders. In particular, RBFOX1
(RNA binding fox-1 homolog 1) regulates YWHAE, YWHAG, YWHAQ and YWHAZ, whereas FMRP
(Fragile X mental retardation protein) binds YWHAG [98,99]. Interestingly, RBFOX1 has been reported
in several ASD genetic studies [97,100–103], as well as in studies of aggressive behaviour and several
psychiatric disorders [74,104–106]. Also, several targets of FMRP have been suggested to play a role in
ASD [98,107,108].
Thus, our results indicate that combined rare variants in 14-3-3 genes may contribute to ASD,
and that common variants from 14-3-3 family members significantly associate with schizophrenia.
Also, when 14-3-3 genes are considered individually, rare variants in the YWHAZ gene are shown to
contribute to schizophrenia.
Finally, we have systematically gathered and analysed previous transcriptomic data that suggest
significant alteration of the expression of 14-3-3 genes in ASD and schizophrenia in several brain
regions. Altered levels of the 14-3-3 family have previously been reported in ASD and in schizophrenia
patients: 14-3-3 protein levels are diminished in platelets and pineal glands in ASD patients [29,44]
and 14-3-3ζ levels are reduced in post-mortem brains of schizophrenia patients [109]. Moreover, an
increased expression of SFN and decreased expression of YWHAB, YWHAE, YWHAG and YWHAQ
mRNA have been reported in leukocytes of schizophrenia patients [45]. Our analysis of available
transcriptomic data is in line with these results, as we found an altered brain expression of six of
the seven 14-3-3 genes in ASD and schizophrenia patients: a robust increased expression of SFN
in both ASD and schizophrenia (reflecting the top 9th and 36th differentially expressed gene in the
transcriptome, respectively [110]; and a decreased expression of the other five 14-3-3 genes).
5. Conclusions
Our work combines functional studies, association studies, sequencing of a European sample,
and interrogation of available genetic datasets that implicate the 14-3-3 gene family in ASD and
schizophrenia, suggesting shared genetics between these two disorders.
J. Clin. Med. 2020, 9, 1851 15 of 21
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/6/1851/s1:
Supplementary file containing: Additional methodological procedures; Table S1. Acceptor and donor combinations
of plasmids for BRET experiments, Table S2. European ASD samples genotyped in the case-control association
study and used in the mutation screening. After quality control procedures the final genotyped sample consisted
of 713 ASD cases and 692 controls, Table S3. Results from the ASD case-control association study (713 ASD cases
and 692 controls) with tagSNPs across the 14-3-3 gene family in the overall sample under the additive model,
Table S4. Description of the summary statistics of publicly available GWAS data of eight psychiatric disorders
and the corresponding cross-disorder dataset used for gene-based and gene-set analyses, Table S5. Experimental
design of targeted next-generation sequencing: The coding regions of 14-3-3 genes was covered by 57 amplicons,
Table S6. Gene-set association results of the 14-3-3 family set of genes on eight different psychiatric phenotypes
and in the cross-disorder meta-analysis dataset, Table S7. Rare variants identified in the seven 14-3-3 family genes
in 287 288 European ASD patients, Figure S1. Linkage disequilibrium values among the 37 tagSNPs analyzed
in this study, calculated from the whole sample (1441 individuals with European ancestry) with the Haploview
software. D’ values between all the possible SNP pairs are shown, Figure S2. The 57 amplicons used in the
mutational screening are depicted in green and cover the coding regions of the 14-3-3 genes. For each of the seven
genes we show the amplicon ID name, the number of overlapping amplicons per exon and the genomic region,
Figure S3. Negative controls in the BRET experiments of the interaction of YWHAZ WT or YWHAZ mutant (mut)
with YWHAE using D(1A) dopamine receptor as a donor (DRD1-Rluc) or an acceptor (DRD1-YFP) and adjusted
to a linear regression, Figure S4. Characterization of three rare inherited SFN variants identified in an ASD patient.
Author Contributions: Conceptualization: B.T., E.A.-G., N.F.-C., C.T., B.C.; Investigation, formal analysis
and validation: B.T., E.A.-G., N.F.-C., E.R.-F., S.G., R.K., E.M., L.P.-C., C.T.; Resources and patients: J.M.F.,
J.H., V.C., A.H., I.R., J.K.B., N.R., B.F., A.G.C., C.F., A.R.; B.C., Writing—Original Draft Preparation: E.A.-G.,
N.F.-C.; Writing—Review and Editing: J.M.F., R.K., C.T., B.C.; Supervision: N.F.-C., R.K., C.T., B.C.; Project
Administration, B.C.; Funding Acquisition: C.T. and B.C. All authors have read and agreed to the published
version of the manuscript.
Funding: Financial support was received from Fundació La Marató de TV3 (092010), Fundación Alicia Koplowitz,
AGAUR (2017SGR738, 2017SGR1497), the Spanish Ministerio de Economía y Competitividad with FEDER funds
(SAF2015-68341-R, SAF2017-87629-R, RTI2018-100968-B-I00) and the Australian National Medical and Health
Research Council (NHMRC) Project Grant 1063960 and 1066177, and Program Grant 1037196. The research
leading to these results also received funding from the European Union H2020 Program (H2020/2014-2020)
under grant agreements 667302 (CoCA) and 643051 (MiND). B. Torrico was supported by AGAUR (Generalitat
de Catalunya), E. Antón-Galindo by the Ministerio de Economía y Competitividad (Spanish Government), N.
Fernàndez-Castillo by the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) and L.
Pineda-Cirera by the Spanish Ministerio de Educación, Cultura y Deporte (FPU15/ 03867). C. Toma was supported
by the European Union (Marie Curie, PIEF-GA-2009-254930) and currently is a recipient of a ‘Ramón y Cajal’
fellowship (RyC2018-024106-I) from the Spanish MINECO. J.M. Fullerton was supported by the Janette Mary
O’Neil Research Fellowship.
Acknowledgments: The authors are grateful to all patients and their families for their participation and thank all
clinical collaborators who contributed to the diagnosis of probands. The authors acknowledge the contribution of
data from dbGAP: phs000473.v2.p2 (Sweden-Schizophrenia population-based case-control) and phs000298.v3.p2
(ARRA Autism Sequencing Collaboration). Sequencing services were provided by the Centre for Research in
Agricultural Genomics (CRAG), Barcelona, Spain.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders; American Psychiatric
Association: Washington, DC, USA, 2013.
2. Toma, C. Genetic variation across phenotypic severity of autism. Trends Genet. 2020, 36, 228–231. [CrossRef]
3. Hodges, H.; Fealko, C.; Soares, N. Autism spectrum disorder: Definition, epidemiology, causes, and clinical
evaluation. Transl. Pediatr. 2020, 9, S55–S65. [CrossRef] [PubMed]
4. Christensen, D.L.; Maenner, M.J.; Bilder, D.; Constantino, J.N.; Daniels, J.; Durkin, M.S.; Fitzgerald, R.T.;
Kurzius-Spencer, M.; Pettygrove, S.D.; Robinson, C.; et al. Prevalence and characteristics of Autism spectrum
disorder among children aged 4 years-early autism and developmental disabilities monitoring network,
seven sites, United States, 2010, 2012, and 2014. MMWR Surveill. Summ. 2019, 68, 1–19. [CrossRef]
5. Ronald, A.; Hoekstra, R.A. Autism spectrum disorders and autistic traits: A decade of new twin studies.
Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 2011, 156, 255–274. [CrossRef] [PubMed]
6. Tick, B.; Bolton, P.; Happé, F.; Rutter, M.; Rijsdijk, F. Heritability of autism spectrum disorders: A meta-analysis
of twin studies. J. Child Psychol. Psychiatry Allied Discip. 2016, 57, 585–595. [CrossRef] [PubMed]
J. Clin. Med. 2020, 9, 1851 16 of 21
7. Sandin, S.; Lichtenstein, P.; Kuja-Halkola, R.; Hultman, C.; Larsson, H.; Reichenberg, A. The heritability of
Autism spectrum disorder analysis method B. JAMA 2017, 318, 1182–1184. [CrossRef]
8. Bourgeron, T. From the genetic architecture to synaptic plasticity in autism spectrum disorder.
Nat. Rev. Neurosci. 2015, 16, 551–563. [CrossRef]
9. De Rubeis, S.; Buxbaum, J.D. Recent advances in the genetics of Autism spectrum disorder. Curr. Neurol.
Neurosci. Rep. 2015, 15, 36. [CrossRef]
10. Wang, K.; Zhang, H.; Ma, D.; Bucan, M.; Glessner, J.T.; Abrahams, B.S.; Salyakina, D.; Imielinski, M.;
Bradfield, J.P.; Sleiman, P.M.A.; et al. Common genetic variants on 5p14.1 associate with autism spectrum
disorders. Nature 2009, 459, 528–533. [CrossRef]
11. Anney, R.; Klei, L.; Pinto, D.; Regan, R.; Conroy, J.; Magalhaes, T.R.; Correia, C.; Abrahams, B.S.; Sykes, N.;
Pagnamenta, A.T.; et al. A genome-wide scan for common alleles affecting risk for autism. Hum. Mol. Genet.
2010, 19, 4072–4082. [CrossRef]
12. Weiss, L.A.; Arking, D.E.; Daly, M.J.; Chakravarti, A.; Brune, C.W.; West, K.; O’Connor, A.; Hilton, G.;
Tomlinson, R.L.; West, A.B.; et al. A genome-wide linkage and association scan reveals novel loci for autism.
Nature 2009, 461, 802–808. [CrossRef] [PubMed]
13. Torrico, B.; Chiocchetti, A.G.; Bacchelli, E.; Trabetti, E.; Hervás, A.; Franke, B.; Buitelaar, J.K.; Rommelse, N.;
Yousaf, A.; Duketis, E.; et al. Lack of replication of previous autism spectrum disorder GWAS hits in European
populations. Autism Res. 2017, 10, 202–211. [CrossRef] [PubMed]
14. Grove, J.; Ripke, S.; Als, T.D.; Mattheisen, M.; Walters, R.K.; Won, H.; Pallesen, J.; Agerbo, E.; Andreassen, O.A.;
Anney, R.; et al. Identification of common genetic risk variants for autism spectrum disorder. Nat. Genet.
2019, 51, 431–444. [CrossRef]
15. Geisheker, M.R.; Heymann, G.; Wang, T.; Coe, B.P.; Turner, T.N.; Stessman, H.A.F.; Hoekzema, K.;
Kvarnung, M.; Shaw, M.; Friend, K.; et al. Hotspots of missense mutation identify neurodevelopmental
disorder genes and functional domains. Nat. Neurosci. 2017, 20, 1043–1051. [CrossRef] [PubMed]
16. Iossifov, I.; O’Roak, B.J.; Sanders, S.J.; Ronemus, M.; Krumm, N.; Levy, D.; Stessman, H.A.; Witherspoon, K.T.;
Vives, L.; Patterson, K.E.; et al. The contribution of de novo coding mutations to autism spectrum disorder.
Nature 2014, 515, 216–221. [CrossRef]
17. Roak, O.B.J.; Vives, L.; Girirajan, S.; Karakoc, E.; Krumm, N.; Coe, B.P.; Levy, R.; Ko, A.; Lee, C.; Smith, J.D.; et al.
Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012,
485, 246–250. [CrossRef]
18. Torrico, B.; Shaw, A.D.; Mosca, R.; Vivó-Luque, N.; Hervás, A.; Fernàndez-Castillo, N.; Aloy, P.; Bayés, M.;
Fullerton, J.M.; Cormand, B.; et al. Truncating variant burden in high-functioning autism and pleiotropic
effects of LRP1 across psychiatric phenotypes. J. Psychiatry Neurosci. 2019, 44, 350–359. [CrossRef]
19. Satterstrom, F.K.; Kosmicki, J.A.; Wang, J.; Breen, M.S.; De Rubeis, S.; An, J.-Y.; Peng, M.; Collins, R.; Grove, J.;
Klei, L.; et al. Large-scale exome sequencing study implicates both developmental and functional changes in
the neurobiology of autism. Cell 2020, 180, 568–584. [CrossRef]
20. Bacchelli, E.; Loi, E.; Cameli, C.; Moi, L.; Vega Benedetti, A.; Blois, S.; Fadda, A.; Bonora, E.; Mattu, S.;
Fadda, R.; et al. Analysis of a sardinian multiplex family with autism spectrum disorder points to
post-synaptic density gene variants and identifies CAPG as a functionally relevant candidate gene.
J. Clin. Med. 2019, 8, 212. [CrossRef]
21. Chapman, N.H.; Nato, A.Q.; Bernier, R.; Ankenman, K.; Sohi, H.; Munson, J.; Patowary, A.; Archer, M.;
Blue, E.M.; Webb, S.J.; et al. Whole exome sequencing in extended families with autism spectrum disorder
implicates four candidate genes. Hum. Genet. 2015, 134, 1055–1068. [CrossRef]
22. Toma, C.; Torrico, B.; Hervás, A.; Valdés-Mas, R.; Tristán-Noguero, A.; Padillo, V.; Maristany, M.; Salgado, M.;
Arenas, C.; Puente, X.S.; et al. Exome sequencing in multiplex autism families suggests a major role for
heterozygous truncating mutations. Mol. Psychiatry 2014, 19, 784–790. [CrossRef] [PubMed]
23. Aghazadeh, Y.; Papadopoulos, V. The role of the 14-3-3 protein family in health, disease, and drug
development. Drug Discov. Today 2016, 21, 278–287. [CrossRef] [PubMed]
24. Cornell, B.; Toyo-oka, K. 14-3-3 proteins in brain development: Neurogenesis, neuronal migration and
neuromorphogenesis. Front. Mol. Neurosci. 2017, 10, 1–17. [CrossRef] [PubMed]
25. Hermeking, H.; Benzinger, A. 14-3-3 Proteins in cell cycle regulation. Semin. Cancer Biol. 2006, 16, 183–192.
[CrossRef] [PubMed]
26. Aitken, A. 14-3-3 proteins: A historic overview. Semin. Cancer Biol. 2006, 16, 162–172. [CrossRef]
J. Clin. Med. 2020, 9, 1851 17 of 21
27. Kaplan, A.; Kent, C.B.; Charron, F.; Fournier, A.E. Switching responses: Spatial and temporal regulators of
axon guidance. Mol. Neurobiol. 2014, 49, 1077–1086. [CrossRef]
28. Toma, C.; Rossi, M.; Sousa, I.; Blasi, F.; Bacchelli, E.; Alen, R.; Vanhala, R.; Monaco, A.P.; Järvelä, I.; Maestrini, E.
Is ASMT a susceptibility gene for autism spectrum disorders? A replication study in European populations.
Mol. Psychiatry 2007, 12, 977–979. [CrossRef]
29. Pagan, C.; Goubran-Botros, H.; Delorme, R.; Benabou, M.; Lemière, N.; Murray, K.; Amsellem, F.; Callebert, J.;
Chaste, P.; Jamain, S.; et al. Disruption of melatonin synthesis is associated with impaired 14-3-3 and miR-451
levels in patients with autism spectrum disorders. Sci. Rep. 2017, 7, 2096. [CrossRef]
30. Melke, J.; Goubran Botros, H.; Chaste, P.; Betancur, C.; Nygren, G.; Anckarsäter, H.; Rastam, M.; Ståhlberg, O.;
Gillberg, I.C.; Delorme, R.; et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol. Psychiatry
2008, 13, 90–98. [CrossRef]
31. Toyo-Oka, K.; Wachi, T.; Hunt, R.F.; Baraban, S.C.; Taya, S.; Ramshaw, H.; Kaibuchi, K.; Schwarz, Q.P.;
Lopez, A.F.; Wynshaw-Boris, A. 14-3-3E and Z regulate neurogenesis and differentiation of neuronal
progenitor cells in the developing brain. J. Neurosci. 2014, 34, 12168–12181. [CrossRef]
32. Xu, X.; Jaehne, E.J.; Greenberg, Z.; McCarthy, P.; Saleh, E.; Parish, C.L.; Camera, D.; Heng, J.; Haas, M.;
Baune, B.T.; et al. 14-3-3ζ deficient mice in the BALB/c background display behavioural and anatomical
defects associated with neurodevelopmental disorders. Sci. Rep. 2015, 5. [CrossRef] [PubMed]
33. Cheah, P.S.; Ramshaw, H.S.; Thomas, P.Q.; Toyo-Oka, K.; Xu, X.; Martin, S.; Coyle, P.; Guthridge, M.A.;
Stomski, F.; Van Den Buuse, M.; et al. Neurodevelopmental and neuropsychiatric behaviour defects arise
from 14-3-3ζ deficiency. Mol. Psychiatry 2012, 17, 451–466. [CrossRef] [PubMed]
34. Ikeda, M.; Hikita, T.; Taya, S.; Uraguchi-asaki, J.; Toyo-Oka, K.; Wynshaw-boris, A.; Ujike, H.; Inada, T.;
Takao, K.; Miyakawa, T.T.; et al. Identification of YWHAE, a gene encoding 14-3-3epsilon, as a possible
susceptibility gene for schizophrenia. Hum. Mol. Genet. 2008, 17, 3212–3222. [CrossRef] [PubMed]
35. Jia, Y.; Yu, X.; Zhang, B.; Yuan, Y.; Xu, Q.; Shen, Y.; Shen, Y. An association study between polymorphisms in
three genes of 14-3-3 (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein) family
and paranoid schizophrenia in northern Chinese population. Eur. Psychiatry 2004, 19, 377–379. [CrossRef]
36. Li, Z.; Chen, J.; Yu, H.; He, L.; Xu, Y.; Zhang, D.; Yi, Q.; Li, C.; Li, X.; Shen, J.; et al. Genome-wide association
analysis identifies 30 new susceptibility loci for schizophrenia. Nat. Genet. 2017, 49, 1576–1583. [CrossRef]
[PubMed]
37. Oldmeadow, C.; Mossman, D.; Evans, T.-J.; Holliday, E.G.; Tooney, P.A.; Cairns, M.J.; Wu, J.; Carr, V.; Attia, J.R.;
Scott, R.J. Combined analysis of exon splicing and genome wide polymorphism data predict schizophrenia
risk loci. J. Psychiatr. Res. 2014, 52, 44–49. [CrossRef]
38. Wong, A.H.C.; Macciardi, F.; Klempan, T.; Kawczynski, W.; Barr, C.L.; Lakatoo, S.; Wong, M.; Buckle, C.;
Trakalo, J.; Boffa, E.; et al. Identification of candidate genes for psychosis in rat models, and possible
association between schizophrenia and the 14-3-3η gene. Mol. Psychiatry 2003, 8, 156–166. [CrossRef]
[PubMed]
39. Jacobsen, K.K.; Kleppe, R.; Johansson, S.; Zayats, T.; Haavik, J. Epistatic and gene wide effects in YWHA and
aromatic amino hydroxylase genes across ADHD and other common neuropsychiatric disorders: Association
with YWHAE. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 2015, 168, 423–432. [CrossRef]
40. Grover, D.; Verma, R.; Goes, F.S.; Belmonte-Mahon, P.L.; Gershon, E.S.; McMahon, F.J.; Potash, J.B.; Steele, J.;
Kassem, L.; Lopez, V.; et al. Family-based association of YWHAH in psychotic bipolar disorder. Am. J. Med.
Genet. Part B Neuropsychiatr. Genet. 2009, 150, 977–983. [CrossRef]
41. Liu, J.; Zhang, H.X.; Li, Z.Q.; Li, T.; Li, J.Y.; Wang, T.; Li, Y.; Feng, G.Y.; Shi, Y.Y.; He, L. The YWHAE
gene confers risk to major depressive disorder in the male group of Chinese Han population. Prog. Neuro
Psychopharmacol. Biol. Psychiatry 2017, 77, 172–177. [CrossRef]
42. Yanagi, M.; Shirakawa, O.; Kitamura, N.; Okamura, K.; Sakurai, K.; Nishiguchi, N.; Hashimoto, T.; Nushida, H.;
Ueno, Y.; Kanbe, D.; et al. Association of 14-3-3 ε gene haplotype with completed suicide in Japanese.
J. Hum. Genet. 2005, 50, 210–216. [CrossRef] [PubMed]
43. Garbett, K.; Ebert, P.J.; Mitchell, A.; Lintas, C.; Manzi, B.; Mirnics, K.; Persico, A.M. Immune transcriptome
alterations in the temporal cortex of subjects with autism. Neurobiol. Dis. 2008, 30, 303–311. [CrossRef]
[PubMed]
J. Clin. Med. 2020, 9, 1851 18 of 21
44. Pagan, C.; Delorme, R.; Callebert, J.; Goubran-Botros, H.; Amsellem, F.; Drouot, X.; Boudebesse, C.;
Dudal, K.L.; Ngo-Nguyen, N.; Laouamri, H.; et al. The serotonin-N-acetylserotonin-melatonin pathway as a
biomarker for autism spectrum disorders. Transl. Psychiatry 2014, 4, e479. [CrossRef] [PubMed]
45. Qing, Y.; Sun, L.; Yang, C.; Jiang, J.; Yang, X.; Hu, X.; Cui, D.; Xu, Y.; He, L.; Han, D.; et al. Dysregulated
14-3-3 family in peripheral blood leukocytes of patients with Schizophrenia. Sci. Rep. 2016, 6. [CrossRef]
46. Saia-Cereda, V.M.; Cassoli, J.S.; Schmitt, A.; Falkai, P.; Nascimento, J.M.; Martins-de-Souza, D. Proteomics of
the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination
in schizophrenia brains. Eur. Arch. Psychiatry Clin. Neurosci. 2015, 265, 601–612. [CrossRef]
47. Saia-Cereda, V.M.; Cassoli, J.S.; Martins-de-Souza, D.; Nascimento, J.M. Psychiatric disorders biochemical
pathways unraveled by human brain proteomics. Eur. Arch. Psychiatry Clin. Neurosci. 2017, 267, 3–17.
[CrossRef]
48. Schubert, K.O.; Föcking, M.; Cotter, D.R. Proteomic pathway analysis of the hippocampus in schizophrenia
and bipolar affective disorder implicates 14-3-3 signaling, aryl hydrocarbon receptor signaling, and glucose
metabolism: Potential roles in GABAergic interneuron pathology. Schizophr. Res. 2015, 167, 64–72. [CrossRef]
49. Bruno, D.L.; Anderlid, B.M.; Lindstrand, A.; Van Ravenswaaij-Arts, C.; Ganesamoorthy, D.; Lundin, J.;
Martin, C.L.; Douglas, J.; Nowak, C.; Adam, M.P.; et al. Further molecular and clinical delineation of
co-locating 17p13.3 microdeletions and microduplications that show distinctive phenotypes. J. Med. Genet.
2010, 47, 299–311. [CrossRef]
50. Capra, V.; Mirabelli-Badenier, M.; Stagnaro, M.; Rossi, A.; Tassano, E.; Gimelli, S.; Gimelli, G. Identification of
a rare 17p13.3 duplication including the BHLHA9 and YWHAE genes in a family with developmental delay
and behavioural problems. BMC Med. Genet. 2012, 13, 93. [CrossRef]
51. Nagamani, S.C.S.; Zhang, F.; Shchelochkov, O.A.; Bi, W.; Ou, Z.; Scaglia, F.; Probst, F.J.; Shinawi, M.; Eng, C.;
Hunter, J.V.; et al. Microdeletions including YWHAE in the Miller-Dieker syndrome region on chromosome
17p13.3 result in facial dysmorphisms, growth restriction, and cognitive impairment. J. Med. Genet. 2009, 46,
825–833. [CrossRef]
52. Blazejewski, S.M.; Bennison, S.A.; Smith, T.H.; Toyo-oka, K. Neurodevelopmental genetic diseases associated
with microdeletions and microduplications of chromosome 17p13.3. Front. Genet. 2018, 9, 9. [CrossRef]
[PubMed]
53. Curry, C.J.; Rosenfeld, J.A.; Grant, E.; Gripp, K.W.; Anderson, C.; Aylsworth, A.S.; Saad, T.B.; Chizhikov, V.V.;
Dybose, G.; Fagerberg, C.; et al. The duplication 17p13.3 phenotype: Analysis of 21 families delineates
developmental, behavioral and brain abnormalities, and rare variant phenotypes. Am. J. Med. Genet. Part A
2013, 161, 1833–1852. [CrossRef] [PubMed]
54. Ramocki, M.B.; Bartnik, M.; Szafranski, P.; Kołodziejska, K.E.; Xia, Z.; Bravo, J.; Miller, G.S.; Rodriguez, D.L.;
Williams, C.A.; Bader, P.I.; et al. Recurrent distal 7q11.23 deletion including HIP1 and YWHAG identified in
patients with intellectual disabilities, epilepsy, and neurobehavioral problems. Am. J. Hum. Genet. 2010, 87,
857–865. [CrossRef] [PubMed]
55. Wachi, T.; Cornell, B.; Toyo-oka, K. Complete ablation of the 14-3-3epsilon protein results in multiple defects
in neuropsychiatric behaviors. Behav. Brain Res. 2017, 319, 31–36. [CrossRef]
56. Kim, D.E.; Cho, C.H.; Sim, K.M.; Kwon, O.; Hwang, E.M.; Kim, H.W.; Park, J.Y. 14-3-3Γ haploinsufficient
mice display hyperactive and stress-sensitive behaviors. Exp. Neurobiol. 2019, 28, 43–53. [CrossRef]
57. Graham, K.; Zhang, J.; Qiao, H.; Wu, Y.; Zhou, Y. Region-specific inhibition of 14-3-3 proteins induces
psychomotor behaviors in mice. NPJ Schizophr. 2019, 5, 1. [CrossRef]
58. Ghorbani, S.; Fossbakk, A.; Jorge-Finnigan, A.; Flydal, M.I.; Haavik, J.; Kleppe, R. Regulation of tyrosine
hydroxylase is preserved across different homo-and heterodimeric 14-3-3 proteins. Amino Acids 2016, 48,
1221–1229. [CrossRef]
59. Itagaki, C.; Isobe, T.; Taoka, M.; Natsume, T.; Nomura, N.; Horigome, T.; Omata, S.; Ichinose, H.; Nagatsu, T.;
Greene, L.A.; et al. Stimulus-coupled interaction of tyrosine hydroxylase with 14-3-3 proteins. Biochemistry
1999, 38, 15673–15680. [CrossRef]
60. Kleppe, R.; Rosati, S.; Jorge-Finnigan, A.; Alvira, S.; Ghorbani, S.; Haavik, J.; Valpuesta, J.M.; Heck, A.J.R.;
Martinez, A. Phosphorylation dependence and stoichiometry of the complex formed by tyrosine hydroxylase
and 14-3-3γ. Mol. Cell. Proteom. 2014, 13, 2017–2030. [CrossRef]
J. Clin. Med. 2020, 9, 1851 19 of 21
61. Moreno, E.; Vaz, S.H.; Cai, N.S.; Ferrada, C.; Quiroz, C.; Barodia, S.K.; Kabbani, N.; Canela, E.I.;
McCormick, P.J.; Lluis, C.; et al. Dopamine-galanin receptor heteromers modulate cholinergic
neurotransmission in the rat ventral hippocampus. J. Neurosci. 2011, 31, 7412–7423. [CrossRef]
62. Rutter, M.; LeCouteur, A.; Lord, C. Autism Diagnostic Interview-Revised (ADI-R); Western Psychological
Services: Torrance, CA, USA, 2003.
63. Lord, C.; Rutter, M.; DiLavore, P.; Risi, S.; Gotham, K.; Bishop, L.; RJ, L.; Guthrie, W. Autism Diagnostic
Observation Schedule, 2nd ed.; Western Psychological Services: Torrance, CA, USA, 2012.
64. Miller, S.A.; Dykes, D.D.; Polesky, H.F. A simple salting out procedure for extracting DNA from human
nucleated cells. Nucleic Acids Res. 1988, 6, 1215. [CrossRef] [PubMed]
65. Barrett, J.C.; Fry, B.; Maller, J.; Daly, M.J. Haploview: Analysis and visualization of LD and haplotype maps.
Bioinformatics 2005, 21, 263–265. [CrossRef] [PubMed]
66. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.A.R.; Bender, D.; Maller, J.; Sklar, P.; De
Bakker, P.I.W.; Daly, M.J.; et al. PLINK: A tool set for whole-genome association and population-based
linkage analyses. Am. J. Hum. Genet. 2007, 81, 559–575. [CrossRef] [PubMed]
67. Demontis, D.; Walters, R.K.; Martin, J.; Mattheisen, M.; Als, T.D.; Agerbo, E.; Baldursson, G.; Belliveau, R.;
Bybjerg-Grauholm, J.; Bækvad-Hansen, M.; et al. Discovery of the first genome-wide significant risk loci for
attention deficit/hyperactivity disorder. Nat. Genet. 2019, 51, 63–75. [CrossRef] [PubMed]
68. Tielbeek, J.J.; Johansson, A.; Polderman, T.J.C.; Rautiainen, M.R.; Jansen, P.; Taylor, M.; Tong, X.; Lu, Q.;
Burt, A.S.; Tiemeier, H.; et al. Genome-wide association studies of a broad spectrum of antisocial behavior.
JAMA Psychiatry 2017, 74, 1242–1250. [CrossRef] [PubMed]
69. Meier, S.M.; Trontti, K.; Purves, K.L.; Als, T.D.; Grove, J.; Laine, M.; Pedersen, M.G.; Bybjerg-Grauholm, J.;
Bækved-Hansen, M.; Sokolowska, E.; et al. Genetic variants associated with anxiety and stress-related
disorders: A genome-wide association study and mouse-model study. JAMA Psychiatry 2019, 76, 924–932.
[CrossRef]
70. Stahl, E.A.; Breen, G.; Forstner, A.J.; McQuillin, A.; Ripke, S.; Trubetskoy, V.; Mattheisen, M.; Wang, Y.;
Coleman, J.R.I.; Gaspar, H.A.; et al. Genome-wide association study identifies 30 loci associated with bipolar
disorder. Nat. Genet. 2019, 51, 793–803. [CrossRef]
71. Wray, N.R.; Ripke, S.; Mattheisen, M.; Trzaskowski, M.; Byrne, E.M.; Abdellaoui, A.; Adams, M.J.; Agerbo, E.;
Air, T.M.; Andlauer, T.M.F.; et al. Genome-wide association analyses identify 44 risk variants and refine the
genetic architecture of major depression. Nat. Genet. 2018, 50, 668–681. [CrossRef]
72. Arnold, P.D.; Askland, K.D.; Barlassina, C.; Bellodi, L.; Bienvenu, O.J.; Black, D.; Bloch, M.; Brentani, H.;
Burton, C.L.; Camarena, B.; et al. Revealing the complex genetic architecture of obsessive-compulsive
disorder using meta-analysis. Mol. Psychiatry 2018, 23, 1181–1188. [CrossRef]
73. Ripke, S.; Neale, B.M.; Corvin, A.; Walters, J.T.R.; Farh, K.H.; Holmans, P.A.; Lee, P.; Bulik-Sullivan, B.;
Collier, D.A.; Huang, H.; et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature
2014, 511, 421–427. [CrossRef]
74. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic relationships, novel loci, and
pleiotropic mechanisms across eight psychiatric disorders. Cell 2019, 179, 1469–1482. [CrossRef] [PubMed]
75. De Leeuw, C.A.; Mooij, J.M.; Heskes, T.; Posthuma, D. MAGMA: Generalized gene-set analysis of GWAS
data. PLoS Comput. Biol. 2015, 11, 4. [CrossRef] [PubMed]
76. Kurosaki, T.; Maquat, L.E. Nonsense-mediated mRNA decay in humans at a glance. J. Cell Sci. 2016, 129,
461–467. [CrossRef] [PubMed]
77. Khajavi, M.; Inoue, K.; Lupski, J.R. Nonsense-mediated mRNA decay modulates clinical outcome of genetic
disease. Eur. J. Hum. Genet. 2006, 14, 1074–1081. [CrossRef] [PubMed]
78. Obsil, T.; Obsilova, V. Structural basis of 14-3-3 protein functions. Semin. Cell Dev. Biol. 2011, 22, 663–672.
[CrossRef]
79. Halskau, Ø.J.; Ying, M.; Baumann, A.; Kleppe, R.; Rodriguez-Larrea, D.; Almås, B.; Haavik, J.; Martinez, A.
Three-way interaction between 14-3-3 proteins, the N-terminal region of tyrosine hydroxylase, and negatively
charged membranes. J. Biol. Chem. 2009, 284, 32758–32769. [CrossRef]
80. Uhart, M.; Bustos, D.M. Human 14-3-3 paralogs differences uncovered by cross-talk of phosphorylation and
lysine acetylation. PLoS ONE 2013, 8, 1–16. [CrossRef]
J. Clin. Med. 2020, 9, 1851 20 of 21
81. Rosenquist, M.; Sehnke, P.; Ferl, R.J.; Sommarin, M.; Larsson, C. Evolution of the 14-3-3 protein family: Does
the large number of isoforms in multicellular organisms reflect functional specificity? J. Mol. Evol. 2000, 51,
446–458. [CrossRef]
82. Berg, D.; Holzmann, C.; Riess, O. 14-3-3 Proteins in the nervous system. Nat. Rev. Neurosci. 2003, 4, 752–762.
[CrossRef]
83. Kleppe, R.; Martinez, A.; Døskeland, S.O.; Haavik, J. The 14-3-3 proteins in regulation of cellular metabolism.
Semin. Cell Dev. Biol. 2011, 22, 713–719. [CrossRef]
84. Cabana-Domínguez, J.; Torrico, B.; Reif, A.; Fernàndez-Castillo, N.; Cormand, B. Exploring the genetic
contribution of the dopaminergic and serotonergic pathways in psychiatric disorders. Transl. Psychiatry
2019, 9, 242. [CrossRef]
85. Ribasés, M.; Ramos-Quiroga, J.A.; Hervás, A.; Sánchez-Mora, C.; Bosch, R.; Bielsa, A.; Gastaminza, X.;
Lesch, K.P.; Reif, A.; Renner, T.J.; et al. Candidate system analysis in ADHD: Evaluation of nine genes
involved in dopaminergic neurotransmission identifies association with DRD1. World J. Biol. Psychiatry 2012,
13, 281–292. [CrossRef] [PubMed]
86. Toma, C.; Hervás, A.; Balmaña, N.; Salgado, M.; Maristany, M.; Vilella, E.; Aguilera, F.; Orejuela, C.; Cuscó, I.;
Gallastegui, F.; et al. Neurotransmitter systems and neurotrophic factors in autism: Association study of 37
genes suggests involvement of DDC. World J. Biol. Psychiatry 2013, 14, 516–527. [CrossRef] [PubMed]
87. Treister, R.; Pud, D.; Ebstein, R.P.; Laiba, E.; Gershon, E.; Haddad, M.; Eisenberg, E. Associations between
polymorphisms in dopamine neurotransmitter pathway genes and pain response in healthy humans. Pain
2009, 147, 187–193. [CrossRef]
88. Wood, P.B.; Holman, A.J. An elephant among us: The role of dopamine in the pathophysiology of fibromyalgia.
J. Rheumatol. 2009, 36, 221–224. [CrossRef]
89. Ghorbani, S.; Szigetvari, P.D.; Haavik, J.; Kleppe, R. Serine 19 phosphorylation and 14-3-3 binding regulate
phosphorylation and dephosphorylation of tyrosine hydroxylase on serine 31 and serine 40. J. Neurochem.
2020, 152, 29–47. [CrossRef]
90. Ramshaw, H.; Xu, X.; Jaehne, E.J.; McCarthy, P.; Greenberg, Z.; Saleh, E.; McClure, B.; Woodcock, J.; Kabbara, S.;
Wiszniak, S.; et al. Locomotor hyperactivity in 14-3-3ζ KO mice is associated with dopamine transporter
dysfunction. Transl. Psychiatry 2013, 3, e327. [CrossRef]
91. Qiao, H.; Foote, M.; Graham, K.; Wu, Y.; Zhou, Y. 14-3-3 proteins are required for hippocampal long-term
potentiation and associative learning and memory. J. Neurosci. 2014, 34, 4801–4808. [CrossRef]
92. Toyo-Oka, K.; Shionoya, A.; Gambello, M.J.; Cardoso, C.; Leventer, R.; Ward, H.L.; Ayala, R.; Tsai, L.H.;
Dobyns, W.; Ledbetter, D.; et al. 14-3-3ε is important for neuronal migration by binding to NUDEL: A
molecular explanation for Miller-Dieker syndrome. Nat. Genet. 2003, 34, 274–285. [CrossRef]
93. Cornell, B.; Wachi, T.; Zhukarev, V.; Toyo-oka, K. Regulation of neuronal morphogenesis by 14-3-3epsilon
(Ywhae) via the microtubule binding protein, doublecortin. Hum. Mol. Genet. 2016, 25, 4405–4418. [CrossRef]
94. Takahashi, T.; Nakamura, Y.; Nakamura, Y.; Aleksic, B.; Takayanagi, Y.; Furuichi, A.; Kido, M.; Nakamura, M.;
Sasabayashi, D.; Ikeda, M.; et al. The polymorphism of YWHAE, a gene encoding 14-3-3epsilon,
and orbitofrontal sulcogyral pattern in patients with schizophrenia and healthy subjects. Prog. Neuro
Psychopharmacol. Biol. Psychiatry 2014, 51, 166–171. [CrossRef] [PubMed]
95. Kido, M.; Nakamura, Y.; Nemoto, K.; Takahashi, T.; Aleksic, B.; Furuichi, A.; Nakamura, Y.; Ikeda, M.;
Noguchi, K.; Kaibuchi, K.; et al. The polymorphism of YWHAE, a gene encoding 14-3-3epsilon, and brain
morphology in Schizophrenia: A voxel-based morphometric study. PLoS ONE 2014, 9, E103571. [CrossRef]
[PubMed]
96. Lim, E.T.; Uddin, M.; De Rubeis, S.; Chan, Y.; Kamumbu, A.S.; Zhang, X.; D’Gama, A.M.; Kim, S.N.; Hill, R.S.;
Goldberg, A.P.; et al. Rates, distribution and implications of postzygotic mosaic mutations in Autism
spectrum disorder. Nat. Neurosci. 2017, 20, 1217–1224. [CrossRef]
97. De Rubeis, S.; He, X.; Goldberg, A.P.; Poultney, C.S.; Samocha, K.; Cicek, A.E.; Kou, Y.; Liu, L.; Fromer, M.;
Walker, S.; et al. Synaptic, transcriptional and chromatin genes disrupted in Autism. Nature 2014, 515,
209–215. [CrossRef] [PubMed]
98. Darnell, J.C.; Van Driesche, S.J.; Zhang, C.; Hung, K.Y.S.; Mele, A.; Fraser, C.E.; Stone, E.F.; Chen, C.; Fak, J.J.;
Chi, S.W.; et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and Autism. Cell
2011, 146, 247–261. [CrossRef]
J. Clin. Med. 2020, 9, 1851 21 of 21
99. Lee, J.A.; Damianov, A.; Lin, C.H.; Fontes, M.; Parikshak, N.N.; Anderson, E.S.; Geschwind, D.H.; Black, D.L.;
Martin, K.C. Cytoplasmic Rbfox1 regulates the expression of synaptic and autism-related genes. Neuron
2016, 89, 113–128. [CrossRef]
100. Hamada, N.; Ito, H.; Nishijo, T.; Iwamoto, I.; Morishita, R.; Tabata, H.; Momiyama, T.; Nagata, K.I. Essential
role of the nuclear isoform of RBFOX1, a candidate gene for Autism spectrum disorders, in the brain
development. Sci. Rep. 2016, 6, 30805. [CrossRef]
101. Turner, T.N.; Hormozdiari, F.; Duyzend, M.H.; McClymont, S.A.; Hook, P.W.; Iossifov, I.; Raja, A.; Baker, C.;
Hoekzema, K.; Stessman, H.A.; et al. Genome sequencing of Autism-affected families reveals disruption of
putative noncoding regulatory DNA. Am. J. Hum. Genet. 2016, 98, 58–74. [CrossRef]
102. Voineagu, I.; Wang, X.; Johnston, P.; Lowe, J.K.; Tian, Y.; Horvath, S.; Mill, J.; Cantor, R.M.; Blencowe, B.J.;
Geschwind, D.H. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature
2011, 474, 380–386. [CrossRef]
103. Kanduri, C.; Kantojärvi, K.; Salo, P.M.; Vanhala, R.; Buck, G.; Blancher, C.; Lähdesmäki, H.; Järvelä, I.
The landscape of copy number variations in Finnish families with autism spectrum disorders. Autism Res.
2016, 9, 9–16. [CrossRef]
104. Fernàndez-Castillo, N.; Gan, G.; van Donkelaar, M.M.J.; Vaht, M.; Weber, H.; Retz, W.; Meyer-Lindenberg, A.;
Franke, B.; Harro, J.; Reif, A.; et al. RBFOX1, encoding a splicing regulator, is a candidate gene for aggressive
behavior. Eur. Neuropsychopharmacol. 2020, 30, 44–55. [CrossRef] [PubMed]
105. Lal, D.; Pernhorst, K.; Klein, K.M.; Reif, P.; Tozzi, R.; Toliat, M.R.; Winterer, G.; Neubauer, B.; Nürnberg, P.;
Rosenow, F.; et al. Extending the phenotypic spectrum of RBFOX1 deletions: Sporadic focal epilepsy. Epilepsia
2015, 56, e129–e133. [CrossRef] [PubMed]
106. Wen, M.; Yan, Y.; Yan, N.; Chen, X.S.; Liu, S.Y.; Feng, Z.H. Upregulation of RBFOX1 in the malformed cortex of
patients with intractable epilepsy and in cultured rat neurons. Int. J. Mol. Med. 2015, 35, 597–606. [CrossRef]
[PubMed]
107. Budimirovic, D.B.; Kaufmann, W.E. What can we learn about autism from studying fragile X syndrome?
Dev. Neurosci. 2011, 33, 379–394. [CrossRef]
108. Lai, A.; Valdez-Sinon, A.N.; Bassell, G.J. Regulation of RNA granules by FMRP and implications for
neurological diseases. Traffic 2020. [CrossRef]
109. English, J.A.; Pennington, K.; Dunn, M.J.; Cotter, D.R. The neuroproteomics of Schizophrenia. Biol. Psychiatry
2011, 69, 163–172. [CrossRef]
110. Gandal, M.J.; Zhang, P.; Hadjimichael, E.; Walker, R.L.; Chen, C.; Liu, S.; Won, H.; Van Bakel, H.; Varghese, M.;
Wang, Y.; et al. Transcriptome-wide isoform-level dysregulation in ASD, Schizophrenia, and bipolar disorder.
Science 2018, 362. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
